ArticleDigestive diseases and sciences2014
miR-638 suppresses cell proliferation in gastric cancer by targeting Sp2.
Article in Digestive diseases and sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 67 citations in OpenAlex.
- Decreased miR-204 in H. pylori-associated gastric cancer promotes cancer cell proliferation and invasion by targeting SOX4.PloS one · 2014Trial
- Identifying Specificity Protein 2 as a key marker for diabetic encephalopathy in the context of predictive, preventive, and personalized medicine.The EPMA journal · 2025Article
- Epigenetically Regulating Non-coding RNAs in Colorectal Cancer: Promises and Potentials.Middle East journal of digestive diseases · 2025Review
- Circular RNA SNX27 Facilitates Gastric Cancer Progression By Sponging miR-638.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Specificity Proteins (Sp) and Cancer.International journal of molecular sciences · 2023Review
- Comprehensive analyses of the microRNA-messenger RNA-transcription factor regulatory network in mouse and human renal fibrosis.Frontiers in genetics · 2022Article
- miR-638 suppresses proliferation by negatively regulating high mobility group A1 in ovarian cancer cells.Experimental and therapeutic medicine · 2021Article
- HNRNPD interacts with ZHX2 regulating the vasculogenic mimicry formation of glioma cells via linc00707/miR-651-3p/SP2 axis.Cell death & disease · 2021Article
- Exosomes Released from CaSR-Stimulated PMNs Reduce Ischaemia/Reperfusion Injury.Oxidative medicine and cellular longevity · 2021Article
- Src-1 and SP2 promote the proliferation and epithelial-mesenchymal transition of nasopharyngeal carcinoma.Open medicine (Warsaw, Poland) · 2021Article
- Sp2 promotes invasion and metastasis of hepatocellular carcinoma by targeting TRIB3 protein.Cancer medicine · 2020Article
- miR-638 acts as an oncogene and predicts poor prognosis in renal cell carcinoma.American journal of translational research · 2020Article
- Upregulated expression of G9a is correlated with poor prognosis of gastric cancer patients.Medicine · 2019Article
- MicroRNA-638 inhibits human aortic valve interstitial cell calcification by targeting Sp7.Journal of cellular and molecular medicine · 2019Article
- A mathematical model as a tool to identify microRNAs with highest impact on transcriptome changes.BMC genomics · 2019Article
- miR-188 Inhibits Glioma Cell Proliferation and Cell Cycle Progression Through Targeting β-Catenin.Oncology research · 2018Article
- Expression of microRNA 638 and sex-determining region Y-box 2 in hepatocellular carcinoma: Association between clinicopathological features and prognosis.Oncology letters · 2018Article
- Minority stress and leukocyte gene expression in sexual minority men living with treated HIV infection.Brain, behavior, and immunity · 2018Article
- Extract of Stellerachamaejasme L(ESC) inhibits growth and metastasis of human hepatocellular carcinoma via regulating microRNA expression.BMC complementary and alternative medicine · 2018Article
- MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells.Bioscience reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs play important roles in the development and progression of various cancers. Recent studies have shown that miR-638 was downregulated in several tumors; however, its role in gastric cancer (GC) has not been investigated in detail.
aimsThe purpose of this study was to determine the role of miR-638 and to elucidate its regulatory mechanism in GC.
methodsThe expression levels of miR-638 and specificity protein 2 (Sp2) were detected by real-time PCR and Western blotting in GC. After pcDNA6.2-GW/EmGFP-miR-638 vector, miR-638 inhibitor and Sp2-siRNA transfection, the AGS cell proliferation was investigated by MTT assay and cell cycle, and apoptosis was detected using the Annexin V/PI. In addition, the regulation of Sp2 by miR-638 was evaluated by real-time RT-PCR, Western blot and luciferase reporter assays; cyclin D1 expression was measured by Western blotting.
resultsThe expression of miR-638 is dramatically down-regulated and Sp2 expression is remarkably up-regulated in GC tissues. Luciferase assays revealed that miR-638 inhibited Sp2 expression by targeting the 3'-UTR of Sp2 mRNA. Overexpression of miR-638 and Sp2-siRNA reduced Sp2 expression at both the mRNA and protein levels in vitro, and inhibition of miR-638 increased Sp2 expression. Moreover, we found that miR-638 overexpression and Sp2-siRNA markedly suppressed cell proliferation with decreasing expression of cyclin D1 and inducing G1-phase cell-cycle arrest in vitro; inhibition of miR-638 significantly promoted cell proliferation by increasing expression of cyclin D1 and leading more cells into the S and G2/M phase.
conclusionsOur results demonstrated that miR-638 suppressed GC cell proliferation by targeting Sp2 with influence on the expression of cyclin D1. We suggest that miR-638 might be a candidate predictor or an anticancer therapeutic target for GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.